APOA1 and COVID-19: The impairment of apoA-I might be associated with a higher risk of COVID-19 and the slower removal and clearance of SARS-CoV-2, as shown in Figure 1A. Compared to commercial HDL, native HDL (lane 1, Figure 1A), which exerts antiviral activity against SARS-CoV-2, did not show a minor band, as recently reported [9].